Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015;4(2):71-8.
doi: 10.2217/cns.14.60.

Depression screening in patients with brain tumors: a review

Aiste Pranckeviciene  1 , Adomas Bunevicius
Affiliations
Review

Depression screening in patients with brain tumors: a review

Aiste Pranckeviciene et al. CNS Oncol. 2015.

Abstract

Brain tumor (BT) is often a devastating disease associated with poor prognosis. Depression is a common complication in BT patients that often remains under-recognized and untreated. Implementation of reliable depression screening algorithms in routine neuro-oncology setting could potentially improve recognition of depression. The Hospital Anxiety and Depression scale-Depression subscale and Patient Health Questionnaire-9 demonstrated adequate psychometric properties for depressive disorder screening in glioma patients. Patients screened positive for depression should be referred for detailed psychiatric assessment prior to initiating anti-depressive treatment. Further methodologically rigorous studies investigating psychometric properties of single-item and multiple-item depression scales are urgently warranted. Studies evaluating anti-depressive treatments' efficacy and clinical value of depression biomarkers are important avenues for future research endeavors in BT patients.

Keywords: brain tumors; depression; diagnostic accuracy; screening.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

References

    1. Parkin D, Whelan S, Ferley J, Teppo L, Thomas DB, editors. Cancer Incidence in Five Continents (Volume VIII) IARC Sci. Publ.; Lyon, France: 2002. - PubMed
    1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005;352(10):987–996. - PubMed
    1. Basch E. Toward patient-centered drug development in oncology. N. Engl. J. Med. 2013;369:397–400. - PubMed
    1. Bruner DW, Bryan CJ, Aaronson N, et al. Issues and challenges with integrating patient-reported outcomes in clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. J. Clin. Oncol. 2007;25:5051–5057. - PMC - PubMed
    1. Rankin NM, Butow PN, Price MA, Evans A. Views of psycho-oncology health professionals on priority psycho-oncology research questions. Support Care Cancer. 2011;19(8):1133–1141. - PubMed

LinkOut - more resources